Condition: Renal Cell Carcinoma · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Alaska Oncology and Hematology ( Site 0133) | Anchorage, Alaska, United States | Recruiting |
| Providence Medical Foundation ( Site 0141) | Fullerton, California, United States | Recruiting |
| Cedars-Sinai Medical Center ( Site 0112) | Los Angeles, California, United States | Recruiting |
| New England Cancer Specialists ( Site 0132) | Westbrook, Maine, United States | Recruiting |
| Greater Baltimore Medical Center ( Site 0145) | Baltimore, Maryland, United States | Recruiting |
| Metro-Minnesota Community Clinical Oncology ( Site 0144) | Saint Louis Park, Minnesota, United States | Recruiting |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131) | Omaha, Nebraska, United States | Recruiting |
| Carolina Oncology Specialists, PA ( Site 9002) | Charlotte, North Carolina, United States | Recruiting |
| Thompson Cancer Survival Center ( Site 0125) | Knoxville, Tennessee, United States | Recruiting |
| Hospital Aleman ( Site 0204) | CABA, Buenos Aires, Argentina | Recruiting |
| Hospital Italiano de Buenos Aires. ( Site 0203) | Caba, Buenos Aires, Argentina | Recruiting |
| Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205) | Caba, Buenos Aires, Argentina | Recruiting |
+ 112 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227402